Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, Board Director of Levicept and Chair of Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Fierce covered our $100M royalty financing agreement with RTW Investments to support the potential U.S. launch of aglatimagene besadenovec (CAN-2409) for localized prostate cancer, pending FDA approval.
We remain on track to submit our BLA in Q4 2026.
https://www.fiercebiotech.com/biotech/candel-glows-brighter-100m-rtw-royalty-deal-fund-prostate-cancer-drugs-launch
Thrilled to share an important milestone for Candel Therapeutics.
Our abstract with new data has been selected for oral plenary presentation in the session “Practice-changing, Paradigm-shifting Clinical Trials in Urology” at the American Urological Association Annual Meeting
Combination therapy approaches will drive improved patient outcomes in oncology.
via @PharmaTechFocus
This @cure_today article explores linoserpaturev (CAN-3110), our viral immunotherapy candidate for recurrent glioblastoma, through the story of Kyle Donahue, a five-year survivor.
https://www.curetoday.com/view/given-months-to-live-shes-now-a-five-year-glioblastoma-survivor
#Glioblastoma #Immunotherapy
